Chinese SOE unable to extricate itself from US antitrust litigation against vitamin C exporters
On 8 February 2013, a New York federal judge denied a motion by North China Pharmaceutical Group Corp for summary judgement in multidistrict antitrust litigation alleging a conspiracy among Chinese companies to fix the price of vitamin C. The judge’s decision illustrates the risks that Chinese parent companies (or even minority shareholders) face when doing business in the US through affiliates, and highlights the need for these parent companies to take steps to insulate themselves from facing costly and burdensome antitrust litigation in the US.
Click on the link above to download this briefing.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
The new Enterprise and Regulatory Reform Act renames compromise agreements ‘settlement agreements’.
The claimant brought various claims against the council, a previous employer from whom she had TUPE transferred and also against a number of individual colleagues.
Analysis from The Lawyer
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies
The Russian legal market faces a new era as the government opens the door to greater business transparency, but not everything is open to scrutiny